Rajal B. Shah
Dr. Charles T. Ashworth Professor of Pathology, University of Texas Southwestern Medical School, Dallas, Texas, USA; and Immediate Past President, Genitourinary Pathology Society (GUPS).
False
Dr. Charles T. Ashworth Professor of Pathology, University of Texas Southwestern Medical School, Dallas, Texas, USA; and Immediate Past President, Genitourinary Pathology Society (GUPS).
What’s the biggest challenge facing your specialty right now, and how are you addressing it via leadership?
Consistent, evidence-based recommendations underpin standardised reporting and clear communication between pathologists and clinicians. When international guidance differs, however, diagnostic consistency and patient management may be affected.
In 2019, the genitourinary pathology community faced this challenge when two international organisations – the Genitourinary Pathology Society (GUPS) and the International Society of Urological Pathology (ISUP) – issued conflicting recommendations on whether intraductal carcinoma of the prostate should be incorporated into the Gleason score for invasive prostate cancer. This disagreement created prolonged uncertainty for pathologists and clinicians, with potential implications for patient management.
At the same time, debate intensified over whether Grade Group 1 prostate cancer, which is often indolent, should be reclassified as “non-cancer” to reduce overtreatment.
When I became President of GUPS in 2024, I recognised that resolving these longstanding issues required collaboration beyond individual institutions. Joint guidance from GUPS and ISUP was essential to restoring consistency, so I initiated discussions with the President of ISUP.
To address the controversy surrounding intraductal carcinoma of the prostate, I co-led a joint consultation involving 32 international experts from both organisations. We used a modified Delphi process that included iterative discussions, predefined consensus thresholds, and input from the wider professional community. The panel reached consensus on an issue that had divided the field for five years. The resulting practice recommendations were recently published in Histopathology and may inform future guidance from other organisations, including the WHO and the College of American Pathologists.
Simultaneously, addressing the debate surrounding the renaming of GG1 prostate cancer demanded rigorous academic leadership. I co-led and authored a high-impact white paper addressing this critical issue, published in European Urology and the full version in The American Journal of Surgical Pathology. This landmark publication will provide the global medical community with a pragmatic, clear, and scientifically balanced pathway forward.
True leadership is defined by the ability to build bridges where there is deep discord. By aligning the two premier societies in our field, this initiative successfully replaced years of professional confusion with unified practicing guidelines. I am immensely proud to have guided GUPS and the broader urological pathology community toward a collaborative future that directly optimizes standardized reporting and elevates the quality of patient care worldwide.
Dive deeper into the world of pathology. Explore the latest articles, case studies, expert insights, and groundbreaking research.
Receive the latest pathologist news, personalities, education, and career development – weekly to your inbox.

False
False
Affiliations:
Specialties:
Areas of Expertise:
False